



# Reintervention and mortality risk after total anomalous pulmonary venous connection repair

## Original Article

**Cite this article:** Beers KM, Jacobsen CP, Miller SR, Lehenbauer DG, Maldonado E, Husain SA, and Calhoun JH (2023) Reintervention and mortality risk after total anomalous pulmonary venous connection repair. *Cardiology in the Young* **33**: 2228–2235. doi: [10.1017/S1047951122004280](https://doi.org/10.1017/S1047951122004280)

Received: 14 September 2022  
Revised: 21 November 2022  
Accepted: 26 December 2022  
First published online: 13 January 2023

### Keywords:

Paediatric cardiac surgery; total anomalous pulmonary venous connection; reintervention (pulmonary vein stenosis)

### Author for correspondence:

Kevin M. Beers, DO. 92 W. Miller Street, MP 307, Orlando, FL 32806, USA. Tel: +1 (321) 841 6128; Fax: +1 (407) 841 4260.  
E-mail: [Kevin.beers@orlandohealth.com](mailto:Kevin.beers@orlandohealth.com)

Kevin M. Beers<sup>1</sup> , Christian P. Jacobsen<sup>2</sup>, Stewart R. Miller<sup>3</sup>, David G. Lehenbauer<sup>4</sup> , Elaine Maldonado<sup>2</sup>, S. Adil Husain<sup>5</sup> and John H. Calhoun<sup>2</sup>

<sup>1</sup>Department of Pediatric Cardiovascular Surgery, Arnold Palmer Hospital for Children, Orlando, FL, USA; <sup>2</sup>Department of Cardiothoracic Surgery, University of Texas Health San Antonio, San Antonio, TX, USA; <sup>3</sup>University of Texas San Antonio College of Business, San Antonio, TX, USA; <sup>4</sup>Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA and <sup>5</sup>Department of Surgery and Pediatrics, University of Utah Health Salt Lake City, UT, USA

### Abstract

**Background:** Management of total anomalous pulmonary venous connections has been extensively studied to further improve outcomes. Our institution previously reported factors associated with mortality, recurrent obstruction, and reintervention. The study purpose was to revisit the cohort of patients and evaluate factors associated with reintervention, and mortality in early and late follow-up. **Methods:** A retrospective review at our institution identified 81 patients undergoing total anomalous pulmonary venous connection repair from January 2002 to January 2018. Demographic and operative variables were evaluated. Anastomotic reintervention (interventional or surgical) and/or mortality were primary endpoints. **Results:** Eighty-one patients met the study criteria. Follow-up ranged from 0 to 6,291 days (17.2 years), a mean of 1263 days (3.5 years). Surgical mortality was 16.1% and reintervention rates were 19.8%. In re-interventions performed, 80% occurred within 1.2 years, while 94% of mortalities were within 4.1 months. Increasing cardiopulmonary bypass times ( $p = 0.0001$ ) and the presence of obstruction at the time of surgery ( $p = 0.025$ ) were predictors of mortality, while intra-cardiac total anomalous pulmonary venous connection type ( $p = 0.033$ ) was protective. Risk of reintervention was higher with increasing cardiopulmonary bypass times ( $p = 0.015$ ), single ventricle anatomy ( $p = 0.02$ ), and a post-repair gradient  $>2$  mmHg on transesophageal echocardiogram ( $p = 0.009$ ). **Conclusions:** Evaluation of a larger cohort with longer follow-up demonstrated the relationship of anatomic complexity and symptoms at presentation to increased mortality risk after total anomalous pulmonary venous connection repair. The presence of a single ventricle or a post-operative confluence gradient  $>2$  mmHg were risk factors for reintervention. These findings support those found in our initial study.

Total anomalous pulmonary venous connection is rare (1–3% of all CHDs) and encompasses a wide clinical spectrum in presentation, from mild cyanosis to cardiovascular collapse.<sup>1–3</sup> With improvement in medical and surgical management, mortality has steadily decreased below 20%, and in some series below 10% in the current surgical era.<sup>1,2,4</sup> In the most recent decade, the focus of the literature has been on identifying characteristics associated with recurrent pulmonary venous obstruction and mortality risk after repair of total anomalous pulmonary venous connection. Our own institution previously reported the association of pulmonary venous obstruction at presentation, increased cardiopulmonary bypass and cross-clamp times with mortality, as well as the association of post-repair confluence gradients with the occurrence of pulmonary venous obstruction requiring reintervention.<sup>1</sup>

Long-term morbidity and mortality data (20–40+ years) exist after total anomalous pulmonary venous connection repair; however, these traverse several decades in which significant improvements in surgical and critical care management of total anomalous pulmonary venous connection have occurred.<sup>2,4,12</sup> With our updated cohort, we focused on the long-term re-intervention and mortality risk in the most recent two decades. The purpose of this study was to revisit our now larger cohort of patients and review factors associated with surgical and long-term mortality as well as the need for re-intervention

### Materials and method

Our study cohort included 81 patients undergoing repair of TAPVC at Christus Santa Rosa Hospital and University Hospital of San Antonio, TX, from January 2002 to January 2018.

**Table 1.** Patient demographics. Demographic variables evaluated in patient cohort.

Covariate	Total	
Age (days) at Repair		
Mean (SD)	44.7	(92.0)
Median	8	
Gender		
Female	28	(34.6)
Male	53	(65.4)
Total	81	
Weight (kg)		
Number	81	
Mean (SD)	3.7	(2.0)
Median	3.3	
TAPVC type		
Supracardiac	42	(51.9)
Intracardiac	15	(18.5)
Infracardiac	16	(19.8)
Mixed	8	(9.0)
Total	81	

Our University of Texas Health at San Antonio program moved from one facility to another in 2014. Approval was granted by the institutional review board at all study group hospitals.

Patient demographics and available operative and post-operative records, discharge summaries, and echocardiographic data were reviewed (Tables 1 and 2). In all patients, the diagnosis of TAPVC was confirmed by transthoracic echocardiogram prior to surgery. Pulmonary venous obstruction was defined as any obstruction of the pulmonary venous drainage along the anomalous pathway, resulting in significant pulmonary congestion and haemodynamic compromise. Study points of interest were mortality and pulmonary vein reintervention. Early, or surgical mortality, was defined as death within 30 days of operation, or at any point during the primary hospitalisation during which initial TAPVC repair occurred. Late mortality was defined as death occurring post-discharge and greater than 30 days from the repair at initial hospitalisation. Reintervention was defined as any procedure, operative or trans-catheter, performed to treat pulmonary venous stenosis/obstruction.

Our study cohort included interventions performed by six different congenital heart surgeons; with two surgeons performing the majority (76.5%) of the primary repairs. All repairs utilised non-absorbable, polypropylene suture.

Post-repair pulmonary venous confluence gradients were measured by an intraoperative transesophageal echocardiogram. Mean gradients were measured at the level of the pulmonary venous confluence anastomosis to the left atrium. Over the study period, transesophageal echocardiogram recordings were performed by two echocardiographers, with the previously reported cohort all being performed by one.

Demographic information including, age and weight at time of operation, gender, single ventricle physiology, heterotaxy, and the presence of pre-operative pulmonary venous obstruction were

**Table 2.** Operative variables evaluated in study cohort.

Covariate, n (%)	Total	
Method of Repair		
Conventional	41	(60.3)
Sutureless	27	(39.7)
Additional Procedures		
Yes	27	(33.3)
No	54	(66.6)
CPB		
Mean (SD)	94	(35.9)
Median	86	
Minimum, maximum	37, 204	
ACC (minutes)		
Mean (SD)	40	(21.3)
Median	35	
Minimum, maximum	10, 122	
Mortality, n (%)		
No	65	(80.2)
Yes	16	(19.8)
Reintervention, n (%)		
No	65	(80.2)
Yes	16	(19.8)
Duration of Hospital Stay		
Mean (SD)	40	(49.3)
Median	22	
Covariate	Obstruction	
Supracardiac	8	(29.6)
Intracardiac	4	(14.8)
Infracardiac	13	(48.1)
Mixed	2	(7.4)
Total	27	
Covariate	Single Ventricle	
Supracardiac	9	(50.0)
Intracardiac	1	(5.6)
Infracardiac	6	(33.3)
Mixed	2	(11.1)
Total	18	
Covariate	Heterotaxy	
Supracardiac	7	(50.0)
Intracardiac	0	
Infracardiac	5	(35.7)
Mixed	2	(14.3)
Total	14	

reviewed. Single ventricle physiology was defined as a cardiac anatomy without the means to provide separate and sufficient systemic and pulmonary circulations. We examined operative

variables, including the method of surgical repair, additional procedures at the time of initial palliation, duration of cardiopulmonary bypass and aortic cross clamp time, utilisation of deep hypothermic circulatory arrest, blood products administered, and immediate postoperative transesophageal echocardiogram findings. Additional procedures were identified and defined as any total anomalous pulmonary venous connection repair requiring more than a patent ductus arteriosus ligation or atrial septal defect repair at the time of initial palliation. Variables of interest were then evaluated for possible association with reintervention, mortality, and hospital length of stay (Tables 3–5).

Study data were collected and managed using the REDCap® (Research Electronic Data Capture) system. Variables in association with outcomes of interest were investigated by statistical methods, including the difference in means (t-test), Pearson's chi-squared analysis, and creation of Kaplan–Meier curves using the log-rank test of equality; all utilising the software STATA 14 © StataCorp LLC, College Station, TX, USA.

## Results

### Patient demographics

Of the 81 patients, 53 (65%) were male and 28 (35%) females. Median age at the time of repair was 8 days (range 0–564 days). Median weight was 3.27 kg (range 2.0 to 16.8 kg). Concerning the anatomic subtypes, 42 (52%) were supracardiac, 15 (19%) intracardiac, 16 (20%) infracardiac, and 8 (9%) had mixed type (Table 1).

Single ventricle physiology was present in 18 (22%) of the 81 patients. Heterotaxy was noted in 14 (17%) patients. At the time of presentation, pulmonary venous obstruction was diagnosed in 27 (33%) of the patients. Among those who presented with obstruction, 13 (48%) were of the infracardiac subtype. Twenty-seven patients (33%) had additional procedures performed at the time of initial total anomalous pulmonary venous connection repair. The most prevalent of these being a right ventricle to pulmonary artery conduit placement (seven patients), pulmonary artery banding (five patients), atrial septectomy (four patients), and coarctation repair (four patients).

### Patient follow-up

Total follow-up time ranged from 0 to 17.2 years, with a median of 8.8 months and a mean of 3.5 years. Follow-up information was available for all 81 patients; however, only 64 and 56 patients had followed up at 30 and 60 days, respectively. Median time between initial date of surgery and mortality was 58 days (range 0 to 44.4 months), with 94% occurring within 4.1 months. The median time between the date of surgery and re-intervention was 97 days (range 3 to 3733 days), with 80% occurring within 1.2 years.

### Operative technique

Of the 81 initial operations, 41 (51%) were considered “conventional”, 28 (35%) operations utilised the sutureless method. The sutureless method of repair was determined from the operative note, with a technique like those reported.<sup>21</sup> The conventional methods of repair included surgical anastomosis between the

**Table 3.** Early mortality. Variables evaluated for association with early mortality after surgical repair.

Covariate	No	Yes	p Value
TAPVC type			
Supracardiac	31	9	0.156
Intracardiac	15	0	0.054
Infracardiac	12	3	0.700
Mixed	7	1	0.739
Gender			
Female	20	6	0.283
Male	45	7	
Additional procedures			
No	46	8	0.510
Yes	19	5	
Heterotaxy			
No	56	11	0.884
Yes	9	2	
Ventricles			
Single ventricle	12	3	0.700
Biventricular	53	10	
Obstruction			
No	46	5	0.025
Yes	19	8	
Gradient (mmHg)			
<2	38	7	0.848
>2	24	5	
Age (days)			
Number	65	13	0.156
Mean	50.8	10.9	
Weight (kg)			
Number	64	13	0.088
Mean	3.9	2.87	
CPB (minutes)			
Number	64	13	0.000
Mean	86.1	122.4	
ACC (minutes)			
Number	65	13	0.768
Mean	39.6	41.5	
CPB (minutes)			
< median	39	2	0.003
> median	25	11	
ACC (minutes)			
< median	36	4	0.105
> median	29	9	

**Table 4.** All mortality. Variables evaluated for association with early or late mortality after surgical repair.

Covariate	No	Yes	p Value
TAPVC type			
Supracardiac	31	11	0.131
Intracardiac	15	0	0.033
Infracardiac	12	4	0.556
Mixed	7	1	0.587
Gender			0.147
Female	20	8	
Male	45	8	
Additional procedures			0.114
No	46	8	
Yes	19	8	
Heterotaxy			0.099
No	56	11	
Yes	9	5	
Ventricles			0.101
Single ventricle	12	6	
Biventricular	53	10	
Obstruction			0.114
No	34	5	
Yes	31	11	
Gradient (mmHg)			0.573
<2	38	8	
>2	24	7	
Mean Gradient	1.5	2.4	0.120
Age (days)			0.231
Number	65	16	
Mean	51	20	
Weight (kg)			0.144
Number	64	16	
Mean	3.9	3.1	
CPB (minutes)			0.000
Number	64	16	
Mean	86	127	
ACC (minutes)			0.670
Number	65	16	
Mean	40	42	
Surgical Repair			0.135
Conventional	35	8	
Sutureless	19	6	
CPB (minutes)			0.001
< median	39	2.0	
> median	25	14	

(Continued)

**Table 4.** (Continued)

Covariate	No	Yes	p Value
ACC (minutes)			0.200
< median	36	6	
> median	29	10	

pulmonary confluence into either the dome of the left atrium, the left atrial appendage, or via a right atriotomy with atrial septostomy and reconstruction. The remaining 12 (14%) were unclassified due to missing or incomplete records. Statistical evaluation of the various methods of repair was not significantly associated with post-operative mortality or re-intervention rates. Cardiopulmonary bypass and aortic cross-clamp times were also evaluated. The median time on cardiopulmonary bypass times was 86 minutes (range of 37 to 204) while median aortic cross-clamp time was 35 minutes (range of 10 to 122). The use of DHCA was utilised in 16 (20.5%) patients. Blood product use including intraoperative transfusion of packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate were noted and analysed for possible association with post-operative mortality and re-intervention. They were not found to be significant regarding re-intervention or mortality (Table 2).

#### Re-intervention for pulmonary venous stenosis

All patients were reviewed for the development of pulmonary venous stenosis at the confluence requiring intervention. There were 16 patients who required re-intervention for significant pulmonary venous obstruction. Of these 16 patients, 5 had multiple reinterventions. Those with single-ventricle anatomy were found to be at significant risk for re-intervention ( $p = 0.021$ ) (Fig 2). Upon cessation of cardiopulmonary bypass, transesophageal echocardiogram evaluation of the venous confluence identified a post-repair gradient greater than 2 mmHg to be significantly associated with re-intervention ( $p = 0.009$ ) (Table 5). Kaplan–Meier curves were created in re-intervention analysis (Fig 2). The log-rank test demonstrated the presence of obstruction as a predictor of re-intervention ( $p = 0.031$ ). A Cox-proportional hazard model was also created, which again found significance in the presence of obstruction and re-intervention rate with a hazard rate of 3.468, and nearly 2.5× higher risk compared to non-obstructed ( $p = 0.042$ ). Kaplan–Meier curves and Cox proportional hazard models for single ventricle and heterotaxy trended toward significance, but ultimately did not reach a  $p$ -value  $< 0.05$ .


#### Mortality

There were 16 (19.8%) total patient deaths throughout the study period. Thirteen (16.1%) were surgical mortalities, and 3 (3.7%) were late deaths. Of note, all three patients with late mortality had single ventricle anatomy in association with heterotaxy. Among these patients, the latest mortality occurred 1322 days post-initial discharge during a subsequent Fontan palliation. The total anomalous pulmonary venous connection anatomic subtypes were evaluated for associated risk with mortality. The overall mortality in repaired supracardiac subtype was 11/42, intracardiac had no death (0/15), infracardiac 4/16 deaths, and mixed 1/8 died. Intracardiac subtype was found to be negatively correlated with mortality ( $p = 0.033$ ), indicating a survival benefit. Single and


**Table 5.** Reintervention. Variables evaluated for association with surgical and/or transcatheter intervention for pulmonary venous confluence obstruction after surgical repair.

Covariate	No	Yes	<i>p</i> Value
TAPVC type			
Supracardiac	36	6	0.200
Intracardiac	11	4	0.456
Infracardiac	13	3	0.910
Mixed	5	3	0.184
Gender			0.369
Female	24	4	
Male	41	12	
Additional procedures			0.324
No	45	9	
Yes	20	7	
Heterotaxy			0.099
No	56	11	
Yes	9	5	
Ventricles			0.021
Single ventricle	11	7	
Biventricular	54	9	
Obstruction			0.114
No	46	8	
Yes	19	8	
TEE Gradient (mmHg)			0.009
<2	42	4	
>2	21	10	
Mean Gradient	1	2.8	0.016
Age (days)			0.480
Number	65	16	
Mean	48	30.1	
Weight (kg)			0.087
Number	65	15	
Mean	4	4.5	
CPB (minutes)			0.411
Number	65	15	
Mean	93	101	
ACC (minutes)			0.252
Number	65	16	
Mean	39	2.5	
Surgical Repair			0.173
Conventional	31	10	
Sutureless	24	3	


biventricular repair patients were evaluated, and while single ventricle repairs had a higher mortality rate, this was not statistically significant.



A. Single (0) vs. Biventricular Physiology (1)




B. Non-Heterotaxy (0) vs. Heterotaxy (1)




A. Non-Obstructed (0) vs. Obstructed (1)

**Figure 1.** Kaplan Meier Curves for re-intervention in subgroups of ventricular physiology, presence of heterotaxy, and presence of pulmonary venous obstruction at presentation.


Within our cohort, 54 patients had no pulmonary venous obstruction at presentation, and 5/54 (9.82%) died after repair. A total of 27 patients presented with pulmonary venous obstruction and 8/27 (29.6%) died. Those patients presenting with obstruction were at increased risk of early mortality ( $p = 0.025$ ). Kaplan–Meier curves were created for mortality analysis. The log-rank test of equality demonstrated significance in the presence of obstruction and mortality ( $p = 0.007$ ) (Fig 2). Cox proportional hazard models were also considered, noting a hazard rate of 3.877 ( $p = 0.014$ ) for the presence of obstruction, indicating a mortality hazard rate of 287% higher than those without obstruction.



A. Single (0) vs. Biventricular Physiology (1)



B. Non-Heterotaxy (0) vs. Heterotaxy (1)



C. Non-Obstructed (0) vs. Obstructed (1)

**Figure 2.** Kaplan Meier Curves for mortality in subgroups of ventricular physiology, presence of heterotaxy, and presence of pulmonary venous obstruction at presentation.

Kaplan–Meier curves and Cox proportional hazard models for single ventricle and heterotaxy trended toward significance, but ultimately did not reach a  $p$ -value  $<0.05$ .

During repair, the length of time on cardiopulmonary bypass, particularly times greater than the median of 86 minutes, were significantly correlated with early and all-mortality ( $p = 0.003$  and  $p = 0.001$ , respectively).

## Discussion

A growing body of literature pertaining to the management and outcomes of patients with total anomalous pulmonary venous connection has brought to light important factors associated with outcomes. Several characteristics of patient anatomy and surgical management have been previously identified as risk factors for reintervention and mortality after surgical repair of total anomalous pulmonary venous connection.<sup>1,4-7,9-13</sup>

Several factors were associated with reintervention for post-operative pulmonary venous obstruction including gender, increased cardiopulmonary bypass, increased aortic cross-clamp times, and post-operative transesophageal echocardiogram confluence gradient  $\geq 2$  mmHg.<sup>1</sup> The initial data published from our institution in 2011 was completed over a relatively short period of five years and follow-up of the younger portion of the cohort was of specific interest. This study contains the original group of 46 patients in addition to 35 patients surgically repaired from 2011 to 2018. Of note, the original study contained 51 patients; however, upon further review of the original patient's records, 5 were removed in our study due to disqualifying factors.

## Reintervention


The incidence of pulmonary venous stenosis (PVS) is cited as occurring in 10–15% of surgically repaired total anomalous pulmonary venous connection and remains a difficult complication to manage in the post-operative period.<sup>15</sup> The location of stenosis can vary, either at the anastomotic site of the confluence, or as an intrinsic disease process affecting the pulmonary veins anywhere throughout their course. More concerning is its progressive nature and mortality rates ranging upwards of 40%.<sup>13</sup>

The total number of patients requiring reintervention was 16 (19.7%), where 5 (6%) of these patients required more than one intervention. Of these procedures, 18 were surgical and 6 were catheter-based interventions. Additionally, 80% of reinterventions occurred within the first 15 months after initial surgical repair. This is consistent with Seale, et al. who noted that when pulmonary venous obstruction occurs, it tends to do so early, rather than late after repair.<sup>13</sup> It is also important to note that four interventions occurred after 15 months and were first time re-interventions. Three were anastomotic in origin, and one intrinsic. Only one went on to have further reintervention.

Among our patients, those with single ventricle physiology were found to be at a statistically higher risk for reintervention compared to those with biventricular physiology. The significant heterogeneity in this population of patients makes it difficult to determine which, if any, specific factors relate to increased risk of reintervention. However, one must certainly consider the anatomic complexity of these patients, as well as lability in physiology as substrate for their high-risk nature.

The evaluation of immediate post-operative confluence gradient by means of transesophageal echocardiogram was found to be a significant predictor of reintervention in our original publication. Once again, significance was found for those with a confluence gradient  $\geq 2$  mmHg.

It is well established that there are many factors that affect echo gradients. Physiologically, pulmonary venous flow is dependent on left atrial and ventricular function and compliance. Both are altered with the ensuing haemodynamic lability



**Figure 3.** Sub-type Survival. Observed 12-month and late survival for anatomic sub-types of TAPVC after repair.

immediately after cardiopulmonary bypass, external compression from the transesophageal echocardiogram probe, and other factors which makes immediate post-repair gradients potentially difficult to interpret. In fact, surgical programmes have published reports identifying operative echocardiogram measurements suggesting confluence obstruction, when in fact, follow-up evaluation demonstrated a widely patent confluence without obstruction.<sup>18</sup> When an elevated confluence gradient is identified at transesophageal echocardiogram, it is the practice of some programmes to withdraw the transesophageal echocardiogram probe, and re-image with a transthoracic probe. Therefore, we would posit it is incumbent from the surgeon's perspective to reflect on the quality of the anastomosis to help guide intraoperative decision-making in relation to echo gradients. We believe the measured transesophageal echocardiogram gradient data remains an important factor in a surgeon's decision-making in whether to consider revising the confluence anastomosis. It is important to note that we do not consider these findings as a certainty to the need for revision, but as a guideline to evaluate the possibility and safety of revising and improving the confluence anastomosis. It also places significant emphasis on the importance of having skilled echocardiographers.

### Mortality

Overall, the reported mortality after surgical repair of total anomalous pulmonary venous connection has continually improved with advancing surgical and medical management over recent decades. Early publications demonstrated mortality risk upwards of 20% or more, while more recent reports demonstrate feasibility of mortality rates below 10%.<sup>2,6-7,12</sup> From 2002 to 2018, our programme saw a surgical mortality rate of 16.1% (13/81) and identified three late deaths. Further evaluation revealed 81% (13/16) of overall mortality were neonatal repairs, a finding linked with increased mortality.<sup>2</sup>

The nature of patient presentation, particularly as a neonate with obstruction, single ventricle physiology, and additional anatomical cardiac anomalies has demonstrated the difficulty in creating equal survival compared to those with simple total anomalous pulmonary venous connection. Amidst advances in the management of total anomalous pulmonary venous connection and the lowering of surgical mortality rates, our programme's growing experience has made us aware of the intricacies that exist within the growing body of literature. Specifically, the ability to identify the subset of patients within the highest risk categories for reintervention and mortality.

There were a total of three patients who were considered late deaths. Two deaths occurred within 4 months, the other at 3 years post-repair. All three patients were single ventricle variants. Overall survival for the entire cohort over the 17.2-year study period was 80.3%, with most of the mortality occurring early. Noting, if one survived the early post-operative period, the late survival in our cohort was excellent at 96% (65/98). This reiterates previously published findings that late survival is excellent for those surviving the initial repair and discharge from the hospital.<sup>2,14</sup>

Within this larger cohort, one new finding identified intracardiac subtype as being protective against mortality. Further evaluation of our intracardiac cohort identified three patients with complex total anomalous pulmonary venous connection, and three presented with obstruction, with the majority being simple and unobstructed. This finding certainly could be related to many of these patients having a relatively benign neonatal course and non-urgent need for repair in simple, non-obstructed forms (Fig 3).

### Limitations

We recognise the limitations of this study, and while we are encouraged by our results, the retrospective nature and small sample size limit our ability to perform and interpret our statistical analyses. Another significant limitation was finding data points of interest in patients from the earlier era, where paper charts have since been destroyed in some instances. Additionally, surgeon preference in certain aspects of operative conduct rather than the lack of standardised surgical management of these patients makes it challenging to generalise our findings. Our study is also limited by difficulties in patient follow-up. Due to the rare nature of this condition, many of our patients come from all over the state of Texas and are lost easily to follow-up after initial repair. For our patients, increased complexity in presentation prevents isolating outcomes to total anomalous pulmonary venous connection, creating uncertainty in our mortality and reintervention rates.

### Conclusion

Total anomalous pulmonary venous connection is still a significant problem with significant mortality in the modern era. This study re-evaluated a larger cohort with increased follow-up and confirmed the previously identified factors of confluence obstruction and increased cardiopulmonary bypass times with mortality risk. Intracardiac type was protective against mortality. Immediate post-operative confluence gradients and single ventricle anatomy increase the risk of post-operative pulmonary venous obstruction requiring reintervention. This illustrates the relationship between anatomical complexity and post-operative outcomes in patients with surgically repaired total anomalous pulmonary venous connection. Our institution reports a surgical mortality rate of 16.1%. While this is consistent with the reported literature, we must continually re-evaluate the risk stratification and management of these patients. Our study also sheds light on an expected timeline for re-intervention and mortality which included four patients with first-time reintervention after 15 months, which can help guide providers in surveillance and management.

**Acknowledgements.** None.

**Financial support.** This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

**Conflicts of interest.** None.

### References

- Husain SA, Maldonado E, Rasch D, et al. Total anomalous pulmonary venous connection: factors associated with mortality and recurrent pulmonary venous obstruction. *Ann Thorac Surg* 2012; 94: 825–831.
- Yong MS, Yaftian N, Griffiths S, et al. Long-term outcomes of total anomalous pulmonary venous drainage repair in neonates and infants. *Ann Thorac Surg* 2018; 105: 1232–1239.
- Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. *J Pediatr* 2008; 153: 807–813.
- Kirshbom PM, Myung RJ, Gaynor WG, et al. Preoperative pulmonary venous obstruction affects long-term outcome for survivors of total anomalous pulmonary venous connection repair. *Ann Thorac Surg* 2002; 74: 1616–1620.
- Yanagawa B, Alghamdi AA, Dragulescu A, et al. Primary sutureless repair for, simple, total anomalous pulmonary venous connection: midterm results in a single institution. *J Thorac Cardiovasc Surg* 2011; 141: 1346–1354.
- St. Louis JD, Harvey BA, Menk JS, et al. Repair of, simple, total anomalous pulmonary venous connection: a review from the pediatric cardiac care consortium. *Ann Thorac Surg* 2012; 94: 133–138.
- Caldarone CA, Najm HK, Kadletz M, et al. Surgical management of total anomalous pulmonary venous drain-age: impact of coexisting cardiac anomalies. *Ann Thorac Surg* 1998; 66: 1521–26.
- Caldarone CA, Najm HK, Kadletz M, et al. Relent-less pulmonary vein stenosis after repair of total anomalous pulmonary venous drainage. *Ann Thorac Surg* 1998; 66: 1514–1520.
- White BR, Ho DY, Faerber JA, et al. Repair of total anomalous pulmonary venous connection: risk factors for postoperative obstruction. *Ann Thorac Surg* 2019; 108: 122–129.
- Hancock Friesen CL, Zurakowski D, Thiagarajan RR, et al. Total anomalous pulmonary venous connection: an analysis of current management strategies in a single institution. *Ann Thorac Surg* 2005; 79: 596–606.
- Michielon G, Di Donato RM, Pasquini L, et al. Total anomalous pulmonary venous connection: long-term appraisal with evolving technical solutions. *Eur J Cardiothorac Surg* 2002; 22: 184–191.
- Karamlou T, Gurofsky R, Al Sukhni E, et al. Factors associated with mortality and reoperation in 377 children with total anomalous pulmonary venous connection. *Circulation* 2007; 115: 1591–1598.
- Seale AN, Uemura H, Webber SA, et al. Total anomalous pulmonary venous connection: outcome of postoperative pulmonary venous obstruction. *J Thorac Cardiovasc Surg* 2013; 145: 1255–1262.
- St. Louis JD, McCracken CE, Turks EM, et al. Long-term transplant-free survival after repair of total anomalous pulmonary venous connection. *Ann Thorac Surg* 2018; 105: 186–192.
- Vanderlaan RD, Caldaron CA. Surgical approaches to total anomalous pulmonary venous connection. In *Semin Thorac Cardiovasc Surg Pediatr Card Surg Ann*. vol. 21, p. 83–91.
- Kelle AM, Backer CL, Gossett JG, et al. Total anomalous pulmonary venous connection: results of surgical repair of 100 patients at a single institution. *J Thorac Cardiovasc Surg* 2010; 139: 1387–1394.
- Gottlieb EA, Andropoulos DB. Current and future trends in coagulation management for congenital heart surgery. *J Thorac Cardiovasc Surg* 2017; 153: 1511–1515.
- Herlong JR, Li JS, Bengur AR, Ungerleider RM. Pulmonary vein Doppler echocardiography after left atrial operation. *Ann Thorac Surg* 1995; 60: 678–680.
- Hsia TY, McQuinn TC, Mukherjee R, et al. Effects of Aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. *Ann Thorac Surg* 2010; 89: 1843–1852.
- Pasquali SK, Hall M, Li JS, et al. Safety of Aprotinin in congenital heart operations: results from a large multicenter database. *Ann Thorac Surg* 2010; 90: 14–21.
- Kilic A, Whitman GJR. Blood transfusions in cardiac surgery: indications, risks, and conservation strategies. *Ann Thorac Surg* 2014; 97: 726–734.
- Lacour-Gayet F, Zoghbi J, Serraf AE, et al. Surgical management of progressive pulmonary venous obstruction after repair of total anomalous pulmonary venous connection. *J Thorac Cardiovasc Surg* 1999; 117: 679–687.